Comments
Loading...

Biomarin Pharmaceutical

BMRNNASDAQ
Logo brought to you by Benzinga Data
$65.66
0.661.02%
At close: -
$65.66
0.000.00%
After Hours: 4:03 PM EDT
Consensus Rating1
Buy
Highest Price Target1
$140.00
Lowest Price Target1
$65.00
Consensus Price Target1
$97.78

Biomarin Pharmaceutical (NASDAQ:BMRN) Stock, Analyst Ratings, Price Targets, Forecasts

Quote.Descriptions.analyst-ratings.

Analyst Trends and Forecast
8
Aug
9
Sep
6
3
Oct
1
Nov
1
Dec
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
3.8
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Cantor Fitzgerald
Wolfe Research
Citigroup
Canaccord Genuity
JP Morgan

1calculated from analyst ratings

Analyst Ratings for Biomarin Pharmaceutical

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Biomarin Pharmaceutical (BMRN) stock?

A

The latest price target for Biomarin Pharmaceutical (NASDAQ:BMRN) was reported by Cantor Fitzgerald on December 12, 2024. The analyst firm set a price target for $90.00 expecting BMRN to rise to within 12 months (a possible 37.07% upside). 54 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Biomarin Pharmaceutical (BMRN)?

A

The latest analyst rating for Biomarin Pharmaceutical (NASDAQ:BMRN) was provided by Cantor Fitzgerald, and Biomarin Pharmaceutical reiterated their overweight rating.

Q

When was the last upgrade for Biomarin Pharmaceutical (BMRN)?

A

The last upgrade for Biomarin Pharmaceutical Inc happened on August 20, 2024 when Bernstein raised their price target to $110. Bernstein previously had a market perform for Biomarin Pharmaceutical Inc.

Q

When was the last downgrade for Biomarin Pharmaceutical (BMRN)?

A

The last downgrade for Biomarin Pharmaceutical Inc happened on October 30, 2024 when William Blair changed their price target from N/A to N/A for Biomarin Pharmaceutical Inc.

Q

When is the next analyst rating going to be posted or updated for Biomarin Pharmaceutical (BMRN)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Biomarin Pharmaceutical, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Biomarin Pharmaceutical was filed on December 12, 2024 so you should expect the next rating to be made available sometime around December 12, 2025.

Q

Is the Analyst Rating Biomarin Pharmaceutical (BMRN) correct?

A

While ratings are subjective and will change, the latest Biomarin Pharmaceutical (BMRN) rating was a reiterated with a price target of $90.00 to $90.00. The current price Biomarin Pharmaceutical (BMRN) is trading at is $65.66, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch